Market Reports Dramatically Undercount the True Size of the EV Electric-Motor Market, New Analysis Finds

Distorted accounting obscures real propulsion costs, rare-earth dependency, and emerging alternatives BOSTON, MA, ...

Top SIEMENS VFD Manufacturers Leading the Industry in Automation Solutions

GUANGZHOU CITY, GUANGDONG PROVINCE, CHINA, February 10, 2026 /EINPresswire.com/ -- Variable Frequency Drives (VFDs) ...
PharmiWeb

New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday

A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous ...
Chromatography Online

AI/ML in Practice: Emery Boston explores assisted active learning (AAL)

In the first instalment of LCGC International's interview series exploring how artificial intelligence (AI)/machine learning ...
eLife

SETDB1 enables development beyond cleavage stages by extinguishing the MERVL-driven two-cell totipotency transcriptional program in the mouse embryo

Conditional genetics and single-embryo RNA-seq show that SETDB1 extinguishes the transient, retroelement-driven transcriptional programs of the totipotent two-cell state to facilitate the exit from ...
Le Lézard

New ECCO data show subcutaneous (SC) infliximab (Remsimatm SC) effectively recaptures and maintains disease control after drug holiday

Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response ...